Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;16(3):308-316.
doi: 10.4168/aair.2024.16.3.308.

Serum MRGPRX2 as a Long-term Biomarker for Iodinated Contrast Media-Induced Anaphylaxis

Affiliations

Serum MRGPRX2 as a Long-term Biomarker for Iodinated Contrast Media-Induced Anaphylaxis

Jin An et al. Allergy Asthma Immunol Res. 2024 May.

Abstract

The diagnosis of anaphylaxis is based on the clinical history. The utility of tryptase measurements in clinical setting is limited. Mas-related G protein-coupled receptor-X2 (MRGPRX2) is expressed in mast cells and is involved in the degranulation of these cells. We evaluated the potential of MRGPRX2 as a diagnostic biomarker in patients with iodinated contrast media (ICM)-induced immediate hypersensitivity reactions (IHRs). A total of 173 patients with documented ICM-induced IHR within 4 months from registration were enrolled and skin tests for the culprit ICM were performed. The time interval was evaluated as the duration between the onset of ICM-induced IHR and the measurement of serum MRGPRX2 levels. Serum MRGPRX2 concentration was determined using an enzyme-linked immunosorbent assay kit. Of the 173 patients, 33 and 140 were included in the anaphylaxis and non-anaphylaxis groups, respectively. Serum MRGPRX2 levels were significantly higher in the anaphylaxis than in the non-anaphylaxis group (29.9 ± 24.1 vs. 20.7±17.5, P = 0.044). Serum MRGPRX2 showed a moderate predictive ability for anaphylaxis, with an area under the curve of 0.61 (P = 0.058). When groups were classified based on the time interval, T1(0-2months) and T2 (2-4months), patients with anaphylaxis had higher MRGPRX2 levels compared to the non-anaphylaxis group in the T2 group (36.5±19.2 vs. 20.5±19.0, P = 0.035). This pilot study shows that serum MRGPRX2 is a potential long-term biomarker for predicting anaphylaxis, particularly ICM-induced anaphylaxis. Further studies are needed to determine the role of MRGPRX2 in anaphylaxis in a larger population of patients with various drug-induced IHRs.

Keywords: Hypersensitivity; anaphylaxis; drug; tryptase.

PubMed Disclaimer

Conflict of interest statement

There are no financial or other issues that might lead to conflict of interest.

Figures

Fig. 1
Fig. 1. Definition of time interval. The time interval was defined as the duration between ICM-induced IHR occurrence and serum MRGPRX2 level measurement at registration.
ICM, iodinated contrast media; IHR, immediate hypersensitivity reaction; MRGPRX2, Mas-related G protein-coupled receptor-X2.
Fig. 2
Fig. 2. Differences in serum MRGPRX2 levels related to anaphylaxis. (A) Serum MRGPRX2 levels were significantly higher in the anaphylaxis group than in the non-anaphylaxis group (29.9 ± 24.1 vs. 20.7 ± 17.5, P = 0.044). (B) The AUC of serum MRGPRX2 for predicting anaphylaxis was 0.61 (P = 0.058) and the cut-off value was 22.3 ng/mL.
MRGPRX2, Mas-related G protein-coupled receptor-X2; AUC, area under the curve.
Fig. 3
Fig. 3. Differences in serum MRGPRX2 levels related to time intervals. The T1 group comprised patients who had a time interval of 0–2 months, and the T2 group comprised patients who had a time interval of 2–4 months. Patients with anaphylaxis had significantly higher MRGPRX2 levels than those in the non-anaphylaxis group in T2 (36.53 ± 19.19 vs. 20.45 ± 18.98, P = 0.035).
MRGPRX2, Mas-related G protein-coupled receptor-X2.

References

    1. Brockow K, Christiansen C, Kanny G, Clément O, Barbaud A, Bircher A, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy. 2005;60:150–158. - PubMed
    1. Guéant-Rodriguez RM, Romano A, Barbaud A, Brockow K, Guéant JL. Hypersensitivity reactions to iodinated contrast media. Curr Pharm Des. 2006;12:3359–3372. - PubMed
    1. Simons FE. Anaphylaxis pathogenesis and treatment. Allergy. 2011;66(Suppl 95):31–34. - PubMed
    1. Ribeiro-Vaz I, Marques J, Demoly P, Polónia J, Gomes ER. Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority. Eur J Clin Pharmacol. 2013;69:673–681. - PubMed
    1. Platzgummer S, Bizzaro N, Bilò MB, Pravettoni V, Cecchi L, Sargentini V, et al. Recommendations for the use of tryptase in the diagnosis of anaphylaxis and clonal mastcell disorders. Eur Ann Allergy Clin Immunol. 2020;52:51–61. - PubMed

LinkOut - more resources